Latest Information Update: 30 Jan 2013
At a glance
- Originator Abbott Japan
- Class Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycobacterium avium complex infections
Most Recent Events
- 14 Feb 2006 No development reported - Preclinical for Mycobacterium avium complex infections in Japan (unspecified route)
- 28 Feb 2003 Dainabot has merged with Hokuriku Seiyaku to form Abbott Japan
- 03 Jan 2002 New profile